Economic Implications and Access Challenges Cost Considerations The economic burden of GLP-1 agonists represents a significant barrier to widespread adoption
Along with its role in lowering blood glucose levels, LIXI has many other functions, such as cardiovascular benefits, delaying gastric emptying, protective effect on pancreatic beta-cells, and increased insulin mRNA expression and hormone secretion (65)
The damage is irreversible
This applies to employer-sponsored plans, marketplace plans, and government programs like Medicare and Medicaid
Pharmaceutical GLP-1 drugs often exceed $1,000 per month without insurance coverage
For significant weight loss, we recommend our weight management programs